Safe-Age Study: A Safety and Tolerability Study of a Nutritional Supplement in Healthy Older Adults

Inclusion Criteria: * Body mass index (BMI) between 22.5 and 29.9 kg/m², inclusive. * High-sensitivity C-reactive protein (hsCRP) levels between 0.7 and 5.0 mg/L, inclusive. * Willingness to provide written informed consent. * Willingness to comply with all study procedures and follow-up visits. * Willingness to avoid major lifestyle changes, including new structured physical training or cognitive training targeting study endpoints, during the study period. Exclusion Criteria: * Presence of chronic, inflammatory, or cardiometabolic disease requiring daily medication. * Uncontrolled diabetes mellitus (fasting blood glucose ≥126 mg/dL). * Hypertension. * Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m². * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2× the upper limit of normal. * White blood cell count \<3500/mm³. * Ongoing or recent acute infection within 2 weeks prior to screening. * Vaccination within 4 weeks prior to screening. * Known allergy or intolerance to N-acetyl-L-cysteine (NAC) or glycine. * Participation in another clinical trial within 90 days prior to screening. * Current or recent use of systemic corticosteroids, immunosuppressants, or chronic pain medications. * neurodegenerative, neurological, or major psychiatric disorders. * History of alcohol or drug abuse based on medical history, physical examination, or investigator judgment. * Current smokers. * Any other condition which, in the opinion of the investigator, may interfere with study participation or safety.